ALSUntangled supports further study of sodium chlorite formulations but warns against oral use
Original source
Sodium Chlorite NP001 (opens in a new tab)ALSUntangled reviewed sodium chlorite formulations for amyotrophic lateral sclerosis (ALS). It said NP001 has a plausible mechanism and preliminary safety and progression findings, while evidence for WF10 remains scant and anecdotal. The review warned that oral sodium chlorite may be toxic and could worsen disease.
Why this matters
The review supports carefully monitored studies of NP001 and WF10, not their established use as ALS treatments. It specifically advises against further oral sodium chlorite use unless its safety and relevant effects in humans are demonstrated.
Limitations and context
This is an independent expert review published in 2013, not a new clinical trial or regulatory decision. The evidence described as preliminary or anecdotal does not establish benefit, and the review does not show that any formulation changes current treatment.